Financial Data and Key Metrics Changes - Insmed reported a strong performance in 2025, with revenue guidance for BRINSUPRI of at least $1 billion in 2026, reflecting confidence in market access and early launch performance [7][8][28] - The company anticipates total revenue in 2026 to be more than double that of 2025, indicating significant growth potential [8][28] - Cash position at the end of 2025 was approximately $1.4 billion, with a cash burn in Q4 including $70 million of one-time items [31][32] Business Line Data and Key Metrics Changes - BRINSUPRI launched with $144.6 million in net revenue in its first full quarter, exceeding expectations [9] - ARIKAYCE showed strong growth, particularly in Japan with a 40% increase compared to 2024, contributing over a quarter of its global revenues [23] - The company is pursuing four Phase III clinical programs for TPIP, which received orphan drug designation for pulmonary arterial hypertension [24][25] Market Data and Key Metrics Changes - The total addressable market for BRINSUPRI in the U.S. is estimated at 500,000 diagnosed patients with non-CF bronchiectasis, with significant room for expansion as only 11,550 new patients started treatment in 2025 [10][11] - The company is focusing on identifying undiagnosed bronchiectasis patients among the 32 million diagnosed with COPD or asthma, which could significantly increase the patient base for BRINSUPRI [14][15][16] Company Strategy and Development Direction - Insmed aims to expand its leadership in bronchiectasis and NTM, with plans to accelerate the U.S. launch of BRINSUPRI while continuing to grow ARIKAYCE [6][7] - The company is also exploring additional DPP-1 inhibitors for respiratory diseases and other indications, indicating a broader strategy for pipeline expansion [38] - Insmed is actively working on outreach and education initiatives to identify potential patients who could benefit from BRINSUPRI [15][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity without needing to raise additional capital, although they may seek capital for business development opportunities [8][33] - Positive early feedback from physicians and patients regarding BRINSUPRI is expected to drive additional prescribing behavior [19][70] - The market access landscape for BRINSUPRI is progressing well, with over 90% of targeted patient lives having access to reimbursement [20][21] Other Important Information - The gross-to-net guidance for BRINSUPRI in 2026 is expected to be in the mid-20s to low 30s percentage range, reflecting good visibility into payer contracting [30][31] - The company is evaluating several business development opportunities to expand its pipeline and support future growth [8][33] Q&A Session Summary Question: Plans to develop other DPP-1 inhibitors within respiratory disease - Insmed intends to bring other DPP-1 inhibitors forward, including INS1033 for rheumatoid arthritis and inflammatory bowel disease, and is also advancing other DPP-1s for respiratory conditions [38] Question: Guidance for BRINSUPRI and patient behavior dynamics - Management is seeing positive metrics across various patient behavior indicators, which supports their confidence in achieving at least $1 billion in revenue for BRINSUPRI [41][42] Question: Trends in scrip data and interest in business development - The launch is performing strongly, and while management does not track Symphony data, they are confident in the trajectory based on internal metrics [45][46] Question: Depth of prescribing and physician behavior - Many physicians are initially prescribing BRINSUPRI to one or two patients, and positive experiences are expected to lead to increased prescribing [68][70] Question: Ex-U.S. contribution to BRINSUPRI guidance - Ex-U.S. contributions for BRINSUPRI in 2026 are expected to be very small, with the majority of revenue coming from the U.S. market [61] Question: Additional capital for business development - Insmed sees a clear path to cash flow positivity based on existing programs, with business development being a separate consideration for potential capital sourcing [63][65]

CRH (NYSE:CRH) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Company ParticipantsAdrian Huerta - DirectorAngel Castillo - Executive DirectorDavid MacGregor - PresidentJim Mintern - CEOKathryn Thompson - CEO and Founding PartnerNancy Buese - CFORandy Lake - COOTom Holmes - Head of Investor RelationsConference Call ParticipantsKeith Hughes - Managing Director and Research AnalystMichael Feniger - Senior AnalystShane Carberry - Research AnalystOperatorGood day, and welcome to the CRH fourth quarter and f ...

CenterPoint Energy (NYSE:CNP) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Company ParticipantsAndrew Weisel - Managing DirectorAnthony Crowdell - Managing DirectorBen Vallejo - VP of Investor RelationsDavid Arcaro - Executive Director, Equity ResearchJason P. Wells - Chair​, President, and CEONicholas Campanella - DirectorShar Pourreza - Managing Director and Head of North American Power, Infrastructure and Utilities​Christopher Foster - EVP and CFOConference Call ParticipantsJeremy Tonet - Research ...

Walmart (NYSE:WMT) Q4 2026 Earnings call February 19, 2026 08:00 AM ET Company ParticipantsChris Nicholas - EVP and COODavid Guggina - EVP and Chief eCommerce OfficerJoe Feldman - Senior Managing Director, Assistant Director of Research, and Founding MemberJohn David Rainey - CFOJohn Furner - CEOLatriece Watkins - EVP and Chief Merchandising OfficerSteph Wissink - SVP of Investor RelationsConference Call ParticipantsChristopher Horvers - Managing Director and Senior Equity Research AnalystChuck Grom - Manag ...

Americold Realty Trust (NYSE:COLD) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker7Welcome to Americold Realty Trust fourth quarter 2025 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. I will now turn the call over to Rich Leland, Vice Preside ...

Financial Data and Key Metrics Changes - In-force premium grew to $1.24 billion, up 31% year-over-year, marking nine consecutive quarters of accelerating growth [5][12] - Revenue increased by 53% to $228 million, significantly outpacing in-force premium growth [13] - Gross profit rose 73% year-over-year to a record $111 million, with adjusted gross profit increasing 69% to $112 million [6][13] - Adjusted EBITDA loss narrowed to $5 million, a $19 million improvement year-over-year [6][18] - Positive adjusted free cash flow of $37 million was generated in Q4, marking the second consecutive year of cash reserve growth [6][12] Business Line Data and Key Metrics Changes - Customer growth was 23%, with approximately 550,000 new customers added in 2025, a 35% increase from the prior year [12] - Gross loss ratio reported at 52%, with a favorable prior period development of 9% driven by home and car products [12][13] - Annual dollar retention remained stable at 85% [14] Market Data and Key Metrics Changes - Pet and car insurance segments are experiencing hypergrowth, with in-force premium growth in the 50s and Europe in triple digits [7][21] - The autonomous car insurance product is expected to significantly impact future growth, with pricing based on real-time data from vehicles [10][11] Company Strategy and Development Direction - The company is focused on leveraging AI technologies to enhance go-to-market operations, pricing, and cross-selling capabilities [8][9] - The autonomous insurance initiative, particularly for Lemonade Autonomous Car, is seen as a key growth driver [10] - The company aims to maintain a competitive advantage through its AI-first culture and technology-driven approach [23][25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving EBITDA profitability in Q4 2026 and for the full year of 2027 [6][41] - The company is committed to investing in R&D and enhancing its technology infrastructure to support future growth [35][36] - Management highlighted the importance of maintaining a strong LTV to CAC ratio while increasing growth spend [30][32] Other Important Information - The company ended the quarter with approximately $1.1 billion in cash and investments, with $250 million required as regulatory surplus [14] - Operating expenses increased by 24% year-over-year, primarily due to growth spending [14][15] Q&A Session Summary Question: Improvement in marketing efficiency and EBITDA guidance - Management indicated that the guidance reflects a strong track record and that they are optimistic about growth in 2026, with plans to reinvest marketing efficiency into growth initiatives [28][30][32] Question: Adjusted EBITDA profitability target and premium to surplus - Management confirmed expectations for positive EBITDA in Q4 2026 and the full year of 2027, with ample surplus to support ambitious growth rates [38][41][42] Question: Integration of AI tools like ChatGPT - Management stated that while they currently use their own AI for customer interactions, they are open to exploring other AI tools in the future [45][49] Question: Autonomous vehicle insurance product and pricing models - Management confirmed that they offer both pay-per-mile and fixed pricing models, emphasizing the precision of their pricing based on real-time data [50][52] Question: Strategic initiatives and cross-selling - Management highlighted the importance of cross-selling and the potential for multiple policies to drive growth, while also focusing on enhancing underwriting capabilities [55][57]

Financial Data and Key Metrics Changes - The company reported a GAAP EPS of $1.60 for the full year and $0.40 for the fourth quarter of 2025 [1][13] - Non-GAAP EPS was $0.45 for the fourth quarter and $1.76 for the full year 2025, reflecting a 9% growth compared to 2024 [5][14] - The company also delivered a 9% dividend per share growth last year [5] Business Line Data and Key Metrics Changes - The Houston Electric business is forecasted to see a peak load demand increase of 50% or an additional 10 gigawatts by 2029, two years earlier than previously planned [4][7] - The company is adding $500 million of incremental capital to its 10-year, $65 billion capital investment plan to fund an additional 765 kV import line [4][11] Market Data and Key Metrics Changes - The company expects to grow non-GAAP EPS at the mid to high end of the 7%-9% long-term annual guidance range through 2028, and 7%-9% annually thereafter through 2035 [6][24] - The company anticipates a return to a more typical and timely filing cadence for rate recovery in 2026, which should support stronger and more consistent recovery throughout the year [15] Company Strategy and Development Direction - The company is focused on executing a strong growth plan, supported by regulatory clarity through 2029 on approximately 80% of its rate base [25] - The company is committed to delivering continued improvements in customer experience and economic development through its diverse growth drivers [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet future demand driven by large load requests and existing system capacity [8][40] - The company highlighted the positive impact of new data center demand and reshoring of advanced manufacturing facilities on growth [7][40] Other Important Information - The company expects to recover approximately 85% of its capital investments through various capital trackers [17] - The adjusted FFO-to-debt ratio was 13.8% at the end of the year, slightly below the targeted cushion [20] Q&A Session Summary Question: Update on transmission planning study and 765 kV line - Management clarified that the $500 million of additional capital for the 765 kV line was separate from the incremental transmission work needed due to accelerated large loads [30][31] Question: Impact of repairs adjustment on equity needs - Management indicated that the repairs adjustment could unlock an incremental $1 billion of CapEx without adding equity, improving balance sheet metrics by 60-70 basis points [33] Question: Growth implications and CapEx timing - Management noted that existing capacity allows for accelerated interconnections, with significant CapEx impacts expected towards the tail end of the decade [40][41] Question: ERCOT's batching process and potential delays - Management expressed confidence that the batching process would be manageable and that they could continue to connect large loads without significant delays [44][45] Question: Excess capacity and customer pricing - Management confirmed that existing capacity would help keep customer bills flat, as fixed costs would be spread over a wider base [51] Question: Update on data center opportunities in Indiana - Management remains optimistic about securing large data center opportunities in Indiana, while focusing on existing capacity in Texas [53] Question: Balance sheet capacity and future divestitures - Management stated that they would remain open-minded about capital recycling and divestitures, depending on the most efficient way to finance growth [84]

Financial Data and Key Metrics Changes - Gentherm reported record revenue of $1.5 billion for 2025, an increase of 2.9% compared to the prior year, or 1.8% when excluding foreign currency translation [12] - Adjusted EBITDA for 2025 was $175 million, representing 11% of sales, down from 12.6% the previous year due to higher material costs and expenses related to footprint realignment [13] - Operating cash flow increased by 7% to $117 million, despite building inventory throughout the year [13][14] Business Line Data and Key Metrics Changes - Automotive climate and comfort solutions revenue increased by 5.8% excluding foreign exchange effects, while other automotive products saw a decline of $28 million due to planned exits [12] - The company generated a commercial funnel totaling over $300 million in lifetime revenue from markets outside of light vehicles, including commercial vehicles and home and office applications [7][8] Market Data and Key Metrics Changes - Fourth quarter climate and comfort solutions revenue outgrew light vehicle production by 820 basis points, indicating strong global performance across product categories [13] - In China, Gentherm experienced strong growth, particularly with global OEMs, and finished the year with 60% of awards from domestic manufacturers [49] Company Strategy and Development Direction - Gentherm is focusing on scaling its core technologies beyond automotive applications, with a strategic combination with Modine Performance Technologies expected to close by the end of the year [6][19] - The merger is projected to create a $2.6 billion market leader with a goal to grow to over $3.5 billion by 2030, emphasizing operational excellence and market diversification [6][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, expecting mid-single-digit growth above market levels in 2026, despite a slight decline in light vehicle production [15] - The company anticipates Adjusted EBITDA margins to improve to approximately 12% in 2026, with expectations for revenue growth driven by new program launches and adjacent market contributions [16][17] Other Important Information - Gentherm's FDA 510(k) submission for the Thermafix system is expected to generate revenue later this year, contributing to the medical segment's growth [9] - The company is prioritizing product lifecycle management and leveraging existing automotive intellectual property to enhance innovation in the medical market [8] Q&A Session Summary Question: Adjacent end markets and revenue expectations - Management confirmed they will continue to pursue adjacent markets, expecting home and office to contribute $50 million to $100 million in revenue by 2028, and anticipate significant contributions from medical products [31][32] Question: Footprint realignment timing and EBITDA expectations for 2027 - Management stated that the footprint transitions remain on track for completion in 2026, with benefits expected to flow through in 2027, leading to a potential step function change in margins [34][35] Question: China market positioning and production turbulence - Management reported strong growth in China, particularly with global OEMs, and emphasized a focus on rebalancing the mix towards domestic OEMs [48][49] Question: Thermafix system and future product launches - Management indicated that revenue from the Thermafix system is expected to start this year, and additional product launches leveraging existing technology are anticipated [52] Question: Opportunities in data centers for valves - Management highlighted potential applications in liquid cooling for data centers, facilitated by the merger with Modine Performance Technologies [53]

Praxis Precision Medicines (NasdaqGS:PRAX) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker12Good day, and thank you for standing by. Welcome to the Praxis Precision Medicines fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one on your telephone. You will then hear an automated message advising y ...

Endava (NYSE:DAVA) Q2 2026 Earnings call February 19, 2026 08:00 AM ET Speaker6Good day, and welcome to the Endava second quarter 2026 results. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press Star, then one on a touchtone phone. To withdraw your question, please press Star and then two. Please no ...